SinoFresh(R) Passes First Key Test for Potential to Control 'Super-Bug'
VENICE, Fla., Aug. 19 /PRNewswire-FirstCall/ -- SinoFresh HealthCare, Inc., (OTC Bulletin Board: SFSH) announced preliminary results today from a successful in vivo pilot study indicating that its patented SinoFresh(R) nasal spray was shown to be useful in controlling the MRSA "super-bug" in the nasal passages. This study utilized a recognized scientific model intended to demonstrate SinoFresh(R) nasal spray's ability to kill MRSA hiding in the nasal passages. These favorable efficacy results follow an earlier, successful in vitro study that was conducted at the Public Health Research Institute under the direction of Dr. Barry Kreiswirth, director of the Tuberculosis Center and Hospital Infections Program.
The study showed that "SinoFresh(R) nasal spray used three times daily appeared to effectively eliminate MRSA in the noses of the test animals while leaving enough normal microbes to keep a normal population in the nasal passages," according to Dr. John Todhunter, consultant to SinoFresh, who oversaw the study conducted at Virion Systems in Rockville, MD.
MRSA (which stands for Methicillin Resistant Staphylococcus aureus) is a growing concern in the health care community. It incubates in the nasal passages and then gets on the skin where it can cause severe, virulent infections. The effect of MRSA can lead to disfigurement and sometimes death. MRSA is also highly antibiotic resistant, making MRSA infections difficult to treat. It is believed that approximately 2 - 3 million persons in the U.S. walk around carrying MRSA in their nasal passages at any time and elimination or severe reduction of nasal MRSA colonies is seen as a potentially important weapon in fighting the spread of MSRA. The antibiotic Mupirocin is currently used to reduce nasal MRSA loads.
SinoFresh(R) nasal spray attacks MRSA in the nasal passages by destroying the "super-bug's" cell walls and membranes by physical means rather than by an antibiotic mechanism involving attack on the metabolism of the microbes as occurs with the use of antibiotics. "Since bacteria can in effect change their metabolism to be resistant to antibiotics, but can't very well change the laws of physics the chances for development of resistance to SinoFresh(R) Nasal Spray's mode of killing them is much lower said Dr. Todhunter."
According to William Wilferth, VP for Research and Development at SinoFresh, "These results have exceeded our expectations. The positive results of this in vivo study gives us the solid scientific platform we have needed in order to advance our efforts to fight MRSA to the next level."
Charles Fust, CEO of SinoFresh, noted that the data reported is extremely encouraging and that there is a significant market need for new methods to address MRSA control which is believed to be as many as 80 to 100 million treatments annually in the United States alone.
About SinoFresh HealthCare, Inc.
SinoFresh HealthCare, Inc. (OTC BB: SFSH.OB - News) is a developer and
marketer of innovative upper respiratory system therapies. The company is
researching broad-spectrum antiseptic approaches to reducing viral,
bacterial and fungal organisms that are suspected to cause pathogenesis of
the mouth, nose and throat. The company's lead product, SinoFresh(R) Nasal
and Sinus Care, is a hygienic cleansing spray that kills germs and removes
other nasal-sinus irritants. The company is also researching how antiseptic
cleansing may alleviate chronic sinus distress, a condition that may affect
37 million Americans annually. SinoFresh(R) products are available in major
retail outlets nationwide. More information is available at
William Wilferth, R. Ph. M.S.
VP Research & Development
SinoFresh HealthCare, Inc.
787 Commerce Drive / Suite 6
Venice, FL 34292
Tel: (941) 488-9090 / e-mail: email@example.com
|SOURCE SinoFresh HealthCare, Inc.|
Copyright©2008 PR Newswire.
All rights reserved